Triomics has raised $15m to further develop its oncology-specialised generative AI (GenAI) platform OncoLLM.
OncoLLM is designed to help cancer centres process oncology data at scale and integrates with health system electronic health records (EHR) to complete specific clinical and administrative tasks.
Triomics Prism software pre-screens oncology patients with upcoming appointments to match them to relevant clinical trials while its Harmony software curates EHR data to support reporting, cohort analysis and precision oncology.
After developing an OncoLLM with the Medical College of Wisconsin, a Triomics trial found that within minutes, the platform could identify 90% of eligible patients for clinical trials – a process that could potentially take weeks for qualified nurses to determine.
The trial also found that OncoLLM surpassed the performance of other large language models (LLM), including Mixtral, Qwen and GPT-3.5, as well as matched the capabilities of GPT-4.
Triomics co-founder and chief technology officer (CTO) Hrituraj Singh commented: “Our investments in our core areas of focus have been deliberate.
“We have successfully merged expertise in two complex functional areas: our AI researchers, who are specialised in customising language models to specific domains, and our clinical staff, who have decades of oncology-specific experience.
“As a result, our software can complement the strengths of these advanced models while also proactively addressing potential flaws, all with the intricacies of cancer research and care in mind.”
Bradley Taylor, chief research informatics officer at the Medical College of Wisconsin and director of the Clinical & Translational Sciences Institute (CTSI) Center for Biomedical Informatics commented: “Most of the solutions on the market today claim they use GenAI, but many lack published evidence.
“Triomics is setting themselves apart by taking a truly collaborative approach to co-developing these models.”
Participants in the Series A fundraising round included Silicon Valley-based firms Lightspeed, Nexus Venture Partners, General Catalyst and Y Combinator.
GlobalData estimates that the total AI market was worth $908.7bn in 2023 and forecasts that it will grow at a compound annual growth rate (CAGR) of 35% from 2022 to 2030. The company forecasts that the global specialised AI application market, which includes GenAI, will be worth $477.6bn in 2030.
